All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Post-remission therapy for patients not proceeding to HSCT
Featured:
Jeffrey Lancet
Gert Ossenkoppele
Charles Craddock
Roland Walter
Jorge Sierra
Yasushi Miyazaki
Gunnar Juliusson
Gail J. RobozDuring the AML Hub Steering Committee meeting, held in November 2023, key opinion leaders met to discuss postremission therapy for patients not proceeding to hematopoietic stem cell transplantation. This recorded session was chaired by Gail Roboz and featured Charles Craddock, Gert Ossenkoppele, Gunnar Juliusson, Jefferey Lancet, Jorge Sierra, Roland Walter, and Yasushi Miyazaki.
Post-remission therapy for patients not proceeding to HSCT
The steering committee discussed current induction strategies, how to optimize remission rates, and the impact of measurable residual disease on treatment decisions. They also considered how various global centers manage patients with NPM1-mutated acute myeloid leukemia in first morphological measurable residual disease-negative remission by polymerase chain reaction who are eligible for transplantation.
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?